Funder
Filière Maladies Rares MUCO-CFTR
Société Française de la Mucoviscidose
Association Vaincre la Mucoviscidose
Publisher
European Respiratory Society (ERS)
Reference10 articles.
1. The French Compassionate Program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508delCFTRvariant
2. Molecular structures reveal synergistic rescue of Δ508 CFTR by Trikafta modulators
3. L'Agence nationale de sécurité du médicament et des produits de santé (ANSM) . Décision du 01/06/2023 – Extension de l'indication du cadre de prescription compassionnelle de Kaftrio (ivacaftor, tezacaftor, élexacaftor) et Kalydeco (ivacaftor). [Decision of 01/06/2023 – Extension of the indication of the compassionate prescription framework of Kaftrio (ivacaftor, tezacaftor, élexacaftor) and Kalydeco (ivacaftor).]. Date last updated: 1 June 2023. https://ansm.sante.fr/actualites/decision-du-01-06-2023-extension-de-lindication-du-cadre-de-prescription-compassionnelle-de-kaftrio-ivacaftor-tezacaftor-elexacaftor-et-kalydeco-ivacaftor
4. The U.S. Food and Drug Administration's Experience with Ivacaftor in Cystic Fibrosis. Establishing Efficacy Using In Vitro Data in Lieu of a Clinical Trial
5. Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献